Clinical Trial Update: An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of LIPO-102 for reducing subcutaneous abdominal adiposity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• LIPO-102

Snippet

Sponsor: Neothetics, Inc | Conditions: Subcutaneous Abdominal Adiposity | Phase 2 | Status: COMPLETED